Biogen announced that it would no longer sell or study Aduhelm, an Alzheimer’s disease treatment that was approved in 2021, due to corporate mistakes and regulatory issues. This marks the end of the road for the drug and serves as a cautionary tale in pharmaceutical history. The decision has significant implications for the biotech industry and Alzheimer’s research. This development was recently discussed on an episode of the Readout LOUD, and here is an edited transcript of that conversation.
Source link
The lessons of Aduhelm, an Alzheimer’s drug that was not to be
